TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Completed · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.

Key facts

Study ID

NCT02100852

Run by

TG Therapeutics, Inc.

People needed

19

Starts

2014-03-12

Expected to finish

2017-11-01

Last updated by the study team

2019-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed Chronic Lymphocytic Leukemia (CLL)
• Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
• Ability to swallow oral medication

You may not qualify if…

• Known hepatitis B virus, hepatitis C virus or HIV infection
• Primary central nervous system lymphoma or known intracranial involvement
• Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months

Where it is running

• TG Therapeutics Investigational Trial Site — Huntsville, Alabama, United States
• TG Therapeutics Investigational Trial Site — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.